## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG 1.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.22)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. The Truth About STERIS plc: Why Wall Street Is Quietly Obsessed (And Why You Should Care)**
- Source: AD HOC NEWS | 20260105T042022 | Bullish | Relevance: 100%
- STERIS plc (STE) is a healthcare giant specializing in infection prevention, sterilization, and endoscopy products crucial for hospitals. While not a social media sensation, its recurring revenue model and essential services make it a valuable long-term holding for investors seeking stability in the healthcare sector. The article advises that STE is a "cop" for patient investors valuing long-term growth over meme stock volatility.

**2. STERIS plc (NYSE:STE) Given Average Recommendation of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20260103T080840 | Bullish | Relevance: 100%
- STERIS plc (NYSE:STE) has received an average "Moderate Buy" rating from nine analysts, with a 12-month average target price of $273.50. The medical equipment provider recently surpassed quarterly earnings estimates and announced a quarterly dividend, setting its FY 2026 EPS guidance between $10.150 and $10.30. Insider transactions show recent stock sales by company executives, while institutional investors have been modifying their holdings in the firm.

**3. Harvey Investment Co. LLC Raises Position in STERIS plc $STE**
- Source: MarketBeat | 20260105T132947 | Somewhat-Bullish | Relevance: 100%
- Harvey Investment Co. LLC increased its stake in STERIS plc (NYSE:STE) by 17.1% during the third quarter, making STERIS its 16th largest position and comprising approximately 2.5% of its holdings. STERIS reported strong Q3 earnings, beating analyst estimates with EPS of $2.47 and revenue of $1.46 billion, and maintains a consensus "Moderate Buy" rating with an average price target of $273.50. Despite insider selling, institutional investors own a significant 94.69% of the company's stock.

**4. Ethic Inc. Has $2.07 Million Stake in STERIS plc $STE**
- Source: MarketBeat | 20260103T060819 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. significantly increased its stake in STERIS plc (NYSE:STE) by 388.2% in Q3, now holding 8,378 shares valued at approximately $2.07 million. This comes as STERIS exceeded Q3 earnings and revenue estimates, providing positive FY2026 guidance. Institutional investors hold a large portion of the stock, while company insiders have recently sold shares.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Forward P/E 23.0x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.3B |
| Beta | 1.03 |
| 52W Range | $203.35 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 23.0 |
| Current P/E | 25.1 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.44% (CS: 46) | Neutral |
| RSI_14 | 52.5 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.067x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $256.64
- **Stop Loss:** $247.22 (3.7% risk)
- **Target:** $266.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $23,354.24
- **Portfolio %:** 23.35%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*